Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying the side effects of azacitidine and to see how well
it works in treating patients with chronic myelomonocytic leukemia.